Visen's long-acting growth hormone under US marketing review



Denmark-based Ascendis Pharma A/S (Nasdaq:ASND) submitted an NDA for its novel long-acting growth hormone (LAGH) therapy TransCon, a human growth hormone (HGH) for use in childhood growth hormone deficiency (GHD), with the US FDA. Visen is a joint venture (JV) between Ascendis and China’s Vivo Capital, and holds exclusive rights to Ascendis's endocrine therapy in mainland China, Hong Kong, Taiwan, and Macau.

TransCon is the world’s only HGH prodrug developed through Ascendis’ proprietary Transient Conjugation technology. It releases unmodified and active HGH in vivo for seven days, and distribution is consistent with its once-daily recombinant (rHGH) counterpart. No long-acting growth hormone is available in the US or EU. TransCon earned EU orphan status for GHD in October 2019, and was later nodded for a Phase III clinical study in pediatric GHD by China’s National Medical Products Administration (NMPA). In April 2020, it earned Orphan Drug Designation (ODD) from the US FDA.

Reference:

Related news
According to GBI analysis, Colombia’s National Food and Drug Surveillance Institute (INVIMA) recently approved Pfizer subsidiary Wyeth’s antihemorrhagic BeneFIX (recombinant coagulation factor IX), Pfizer’s human growth hormone analog Somavert (pegvisomant), and Mundipharma’s antineoplastic Difolta (pralatrexate).
Argentina’s Ministry of Health (MoH) launched six drug procurement procedures in recent days, including one tender and five direct purchases.
Argentina’s Ministry of Health (MoH) last week carried out two direct purchases of hormone replacement therapies and antiretrovirals.
Visen Pharma, a joint venture (JV) between Denmark-based Ascendis Pharma A/S (Nasdaq:ASND) and China’s Vivo Capital, revealed that Ascendis has been awarded US FDA orphan drug designation (ODD) for TransCon hGH (lonapegsomatropin), as a treatment for growth hormone deficiency (GHD).
GBI analysis reveals that Cuba’s Center for State Control of Drugs and Medical Devices (CECMED) last week granted market clearance to AstraZeneca (AZ)’s Forxiga (dapagliflozin), as well as Netherlands-based Pharmathen’s and India-based BDR Pharmaceuticals' first-mover generic versions of Novartis’s Sandostatin LAR (octreotide acetate) and Afinitor/Certican (everolimus) respectively.
Recent news
According to GBI analysis, Colombia’s National Food and Drug Surveillance Institute (INVIMA) recently approved Pfizer subsidiary Wyeth’s antihemorrhagic BeneFIX (recombinant coagulation factor IX), Pfizer’s human growth hormone analog Somavert (pegvisomant), and Mundipharma’s antineoplastic Difolta (pralatrexate).
Argentina’s Ministry of Health (MoH) this week launched two drug procurement processes.
Mexico’s Congress last week passed an Industrial Innovation Protection Law, which was announced last month.
Paraguay's Ministry of Health (MSPBS) this week launched its Drugs and Medical Supplies National Monitoring System, an online platform that keeps track of health products distribution in the public healthcare system as well as their cost.
Germany-based giant Merck KGaA has opened its M Lab Collaboration Center in Pudong, at the heart of the biomedical sciences and research community in Shanghai.
The cloud summit of World Artificial Intelligence Conference (WAIC) held in Shanghai this year saw China’s technology giant Tencent launch iDrug, its first AI-empowered drug research and development (R&D) platform, designed to galvanize novel drug development via technology. iDrug covers the whole process of pre-clinical development: protein structure screening, virtual screening, molecular design and optimization, and synthetic route planning.
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (688266.SH) announced the go-ahead from the National Medical Products Administration (NMPA) to initiate a clinical study for its donafenib combined with Genor Biopharma Co., Ltd’s programmed death-1 (PD-1) inhibitor genolimzumab in advanced hepatocellular carcinoma (HCC), gastric cancer including gastroesophageal junction adenocarcinoma (GC/GEJ), renal cell carcinoma (RCC), colorectal cancer (CRC), and other advanced solid tumors. Donafenib (CM4307) is a small-molecule oral multi-kinase inhibitor with activity against serine-threonine kinase (Raf/MEK/ERK) signaling, vascular endothelial growth factor receptor (VEGFRs) and platelet-derived growth factor receptor (PDGFR), designed to directly and indirectly inhibit tumor cell proliferation and growth.
Analytics Snapshot


Analytics Snapshot